Stories
Symbiotec Pharmalab Targets 20-25% Revenue Growth in FY27 Driven by New Biotech Vertical
C
CNBC TV18•23-09-2026, 11:00
Symbiotec Pharmalab Targets 20-25% Revenue Growth in FY27 Driven by New Biotech Vertical
- •Symbiotec Pharmalab aims for 20-25% consolidated revenue and EBITDA growth in FY27, offsetting Q1 and Q2 drags with strong H2 commercial milestones.
- •The company's core active pharmaceutical ingredient (API) business remains robust, contributing over 90% of revenues with high single-digit growth and nearly 30% EBITDA margins.
- •A new biotechnology contract manufacturing (CMO) and CDMO vertical, backed by a ’400 crore investment in fermentation facilities, is a major growth driver.
- •The new biotech vertical is expected to achieve industry-standard gross margins over 70% and EBITDA margins above 35%, projecting ’300-400 crore in revenue over three years.
- •Symbiotec successfully cleared three USFDA audits at its Rau and Pithampur facilities, with confidence in resolving four procedural observations from a recent Pithampur inspection within 2-3 months.
Key Questions Answered
Symbiotec Pharmalab expects to achieve 20-25% consolidated growth in both revenue and EBITDA for the 2026-27 financial year, driven by commercial milestones in the second half that will help offset earlier margin drags.
The company reported a sluggish 7.4% revenue growth in the first quarter of FY27 due to operational expenses and depreciation kicking in from new businesses where it has heavily invested.
Symbiotec successfully cleared three out of four major audits across its Rau and Pithampur facilities with Establishment Inspection Reports (EIR). Although a fourth audit at Pithampur resulted in four procedural observations, management is confident of receiving the EIR within two to three months.
